Blood type, hormone receptor status, HER2/neu status, and survival in breast cancer: a retrospective study exploring relationships in a phenotypically well-defined cohort.
OBJECTIVE
Altered glycosylation has been associated with oncogenic potential. Relationships of blood types (where expression is due to glycosylation pattern) and HER2/neu (where expression arises due to altered glycosylation) and breast cancer-associated markers like estrogen receptor/progesterone receptor (ER/PR) were examined and related to outcomes in patients with breast cancer.


METHODS
A population-based retrospective study of 426 surgical breast cancer patients examined relationships between (1) patient characteristics, (2) breast tumor characteristics, and (3) outcomes of women diagnosed at the same medical center over a 10-year period relative to specific molecules defined by glycosylation patterns (eg. blood group, HER2/neu) and (4) ER/PR status.


RESULTS
Following stratification by blood group, subjects exhibited significant differences in tumor size with persons in blood groups A and B having greater numbers of tumors ≤ 2 cm and those with blood types AB and O having tumors >2 cm. After adjusting for age, disease stage, and treatment with trastuzumab, tamoxifen, or aromatase inhibitors, no significant differences were observed in 5-year overall and disease-free survival based on blood type grouping. Blood group B was over-represented among the breast cancer cohort compared to the reference population, while blood group AB was under-represented.


CONCLUSIONS
No significant differences were observed in overall and disease-free survival based on blood group. No correlation was noted between HER2/neu, ER or PR status, and blood group type. Among this cohort, HER2/neu positivity was less than 20% and correlated with a 5-year disease-free survival rate ≥ 75% and overall survival of >80% across all blood groups.
Cancer Treatment Centers of America, 1331 East Wyoming Ave, Philadelphia, PA 19124, USA. Eiko.klimant@ctca-hope.com
Eiko
E
Klimant
Ingrid
I
Glurich
Bickol
B
Mukesh
Adedayo A
AA
Onitilo
D000017:ABO Blood-Group System / Q000378:metabolism*; D000367:Age Factors; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006031:Glycosylation; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012189:Retrospective Studies; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage; D000068878:Trastuzumab
D000017:ABO Blood-Group System; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D000068878:Trastuzumab; C508053:ERBB2 protein, human
Am J Hum Genet. 1970 Jul;22(4):464-75
5432291
Cancer. 1984 Nov 1;54(9):1845-9
6478419
J Coll Physicians Surg Pak. 2005 Apr;15(4):230-3
15857597
Glycoconj J. 1997 Feb;14(2):159-73
9111133
Breast Cancer Res Treat. 2005 Mar;90(1):65-70
15770528
Lab Invest. 2005 Jul;85(7):895-907
15880137
Cancer. 1993 May 15;71(10):3044-53
8490832
Cancer Res. 1997 Aug 1;57(15):3092-6
9242430
J Cancer Res Clin Oncol. 1993;119(8):486-92
8509439
Oncogene. 1998 Oct 22;17(16):2087-93
9798679
APMIS. 2000 Jan;108(1):1-28
10698081
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3
12149519
J Pathol. 1996 Aug;179(4):358-69
8869281
J Clin Oncol. 1997 Jul;15(7):2518-25
9215820
Clin Med Res. 2009 Jun;7(1-2):4-13
19574486
J Cell Biol. 1995 Jul;130(2):383-92
7615638
Cancer Detect Prev. 1998;22(6):499-505
9824372
Breast Cancer Res Treat. 2010 Jan;119(1):53-61
19205877
Br Med J (Clin Res Ed). 1985 Mar 2;290(6469):671-3
3918710
Cancer Res. 1989 Feb 15;49(4):945-50
2521456
J Natl Cancer Inst. 2003 Jan 15;95(2):142-53
12529347